Confo Therapeutics forms Scientific Advisory Board as it accelerates development of proprietary drug discovery engine
Ghent, Belgium: 28 February 2019 - Confo Therapeutics, an emerging drug discovery company, today announces the formation of its Scientific Advisory Board (SAB) with four key appointments: Radu Aricescu, Peter Kolb, Graeme Milligan and Jan Steyaert, Founder of Confo Therapeutics, who will serve as Chairman of the SAB.
The SAB will work closely with the management team of Confo Therapeutics as it further develops its proprietary Confo® technology for structure-based drug discovery and advances its pipeline of GPCR modulating compounds to produce drug candidates for human clinical trials.
More info on Confo Therapeutics' website
Next > Bluebee receives Health Data Hosting (HDS) accreditation
Previous > Nexstim Plc Depression Therapy Business Update